Pharmaceutical Anglo-Swedish drug major AstraZeneca (LSE: AZN) says its US subsidiary MedImmune's Oncology group has announced preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to cancer. 21 January 2011